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Abstract
Type I interferons have been typically studied for their effects in the context of bacterial or viral infections. However in this
report, we provide evidence that Interferon-alpha (IFN-a) expressing cells are present in the thymus in the absence of
infection. We show that pDC express the highest level of IFN-a and that MxA, which is exclusively expressed after
engagement of the type I IFN receptor by IFN-a/b, is expressed in normal fetal and post-natal thymus, but not in the
periphery. The highest level of MxA is expressed in mature thymocytes and pDC located in the medulla and at the cortico-
medullary junction. The anti-microbial peptide LL-37, which is expressed in the thymus, when complexed with eukaryotic
nucleic acids, induces the secretion of IFN-a by thymic pDC. This results in the upregulation of MxA expression in responsive
thymocytes. We propose that the secretion of IFN-a in the thymus may function to regulate the rate of T cell development
and modulate the requirements for the selection of developing T cells.
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Introduction
Type I interferons (IFN) are immunomodulatory cytokines that
function to alert cells to the presence of pathogens [1]. Antiviral
activity of type I interferons is mediated by the expression of
interferon stimulated genes (ISG), which is dependent on signaling
through the IFN-a receptor (reviewed in[2]). IFN-a receptor
signaling leads to phosphorylation of STAT1/2 and results in the
expression of interferon regulatory factor 7 (IRF-7), required for
the transcription of downstream ISG. Upregulation of ISG
prevents the spread of viral infection through several mechanisms
including the specific degradation of viral gene products, inhibition
of protein translation, and ultimately apoptotic cell death. One
ISG, Myxovirus resistance A (MxA) has been linked with
resistance to viral infection [3,4,5]. MxA protein inhibits the viral
life cycle at three distinct steps, including nucleocapsid transport to
the nucleus [6], transcription of viral gene products [7], or viral
assembly [8]. Expression of this particular ISG is tightly regulated
and only expressed when IFN-a is secreted [9]. Expression of MxA
has been widely utilized as a bio-marker for secreted IFN-a/b in
both viral and bacterial infections [10,11,12].
In addition to antiviral effects, type I interferons are known to
have immunoregulatory activities, such as suppression of murine T
and B cell development in vivo [13,14,15]. We previously showed
that IFN-a suppresses the development of human T cells in vitro by
inhibiting early steps of T cell development [16]. Thus, in addition
to its antiviral effects, IFN-a may play a regulatory role in the
thymus. We previously identified IFN-a positive cells in normal
thymus tissue in the SCID-hu mouse model [17]. However, both
the nature of the IFN-a expressing cells and the stimulus that
induced IFN-a remained elusive. The purpose of the current study
is to further characterize IFN-a expressing cells in normal thymus
tissue, compare these cells to those found in peripheral lymphoid
tissues, and to examine the trigger for IFN-a production in the
absence of infection.
Although every white blood cell has the ability to produce IFN-
a, plasmacytoid dendritic cells (pDC) are the highest producers of
type I IFN. In the thymus pDC are located in the thymus medulla
[18,19] and play a role in the induction of regulatory T cells
[20,21]. The primary function of peripheral blood and peripheral
lymphoid pDC is to secrete large amounts of IFN-a/b in response
to viral and bacterial infection [18,22,23,24,25,26,27,28]. pDC
sense infection via the expression of the Toll like receptors (TLR) -
7 and -9, which bind single stranded RNA and hypomethylated
CpG DNA motifs, respectively. While thymic pDC show some
immunophenotypic differences compared to peripheral pDC [19],
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to CpG [17].
Peripheral blood pDC may also secrete IFN-a in response to
tissue damage as observed in the skin lesions in psoriasis [29]. In
this case, the TLR-7/9 stimulus is eukaryotic nucleic acids, RNA
or DNA, in complex with an anti-microbial peptide (LL-37)
derived from the CAMP gene [29,30]. LL-37 mRNA is expressed
in the thymus [31], but it has not been investigated whether the
resultant peptide can stimulate thymic pDC in the presence of
autologous DNA or RNA. Given that thymocytes undergoing
negative selection die through induction of apoptosis [32] it is
attractive to speculate that this process provides an ample source of
self-RNA/DNA, which in complex with LL-37 induces the
secretion of IFN-a from pDC.
In this report we not only examine IFN-a expression in
thymocytes, but also expression of surrogate markers that are
indicative of type I interferon receptor signaling activity, including
MxA, IRF-7, and phosphorylated STAT1 (pSTAT1). We report
that IFN-a and MxA are constitutively expressed in normal
postnatal and fetal thymus tissues ex vivo, corroborating our
previous results that IFN-a and MxA are expressed in normal
thymus/liver implants in the SCID-hu mouse [17]. Furthermore,
MxA, IRF-7, and pSTAT1 proteins are preferentially expressed in
mature thymocytes that are located in the thymic medulla. Not
only does this area coincide with the known localization pattern of
pDC, but in addition we observed that pDC constitutively
expressed the highest levels of IFN-a in the normal thymus.
Furthermore low, but reproducible, expression of LL-37 was
detected within the thymic medulla. This, together with our
observation that LL-37 complexed with eukaryotic RNA or DNA
can stimulate pDC to express IFN-a, suggests that thymic pDCs
are involved in LL-37/DNA-RNA induced secretion of IFN-a in
the absence of infection. We speculate that thymic pDC may play
a role in regulating the rate of normal T cell development or alter
the requirements for negative selection.
Materials and Methods
Ethics statement
The use of anonymous thymus, peripheral lymphoid and fetal
liver tissues and peripheral blood mononuclear cells was reviewed
by the UCLA Institutional Review Board (IRB), which concluded
that these activities did not involve human subjects, and therefore
did not require IRB review or certification.
Reagents and mAbs
mAbs CD1a, CD3, CD4, CD8, CD27, CD45RA, CD123, and
STAT1 (pY701); isotype controls IgG1 and IgG2 conjugated with
FITC, PE, PerCP, PE-Cy7 or APC; and goat anti-mouse FITC
were obtained from Becton Dickinson (BD); CD1a conjugated
with PE from Beckman Coulter Immunotech; BDCA4-APC from
Miltenyi Biotec; CD8-APC-Alexa750, CD45RA-PerCP-Cy5.5,
CD1a-Pacific Blue and CD3-650 eFluor (Nano-crystals) from
eBioscience; IFN-a -biotin (Endogen); isotype control IgG2a pure,
Goat anti-Rabbit PE from Caltag; mAb to CD27 from Lab
Vision; Goat anti-mouse IgG1 AlexaFluor-488, Goat anti-mouse
IgG2a AlexaFluor-594, Goat anti-Rabbit AlexaFluor-594, and
Zenon anti IgG2a AlexaFluor-488 from Molecular Probes. mAb
to MxA was generously provided by Drs. Haller and Kochs
(University of Freiburg, Germany). mAb CD1a pure, TBST,
Antibody Diluent, and Target Retrieval Solution were obtained
from DAKO (Carpinteria, CA); rabbit anti-mouse IgG1 pure from
Zymed; mAb IRF-7 from Santa Cruz Biotechnology; mAb LL-37
from Cell Sciences. Mounting Medium for fluorescence was
obtained from Vector Laboratories. Polyoxyethylenesorbitanmo-
nolaurate (Tween-20) was purchased from Sigma-Aldrich, para-
formaldehyde from Polysciences. Recombinant human IFN-a was
obtained from BioSource.
Cell cultures
Fetal tissues were obtained from Advanced Biosciences
Resources; adult PBMC from the UCLA CFAR Virology Core
Laboratory; normal human postnatal thymus specimens from
children undergoing corrective cardiac surgery. Thymocytes were
prepared and cultured, as previously described, in serum-free
medium consisting of IMDM (Omega Scientific) supplemented
with delipidated BSA (Sigma-Aldrich) at 1100 mg/ml, transferrin
(Sigma-Aldrich) at 85 mg/ml, 2 mM glutamine, and penicillin/
streptomycin at 25 U/25 mg/ml[17]. Thymocytes were cultured
at 1–2610
7 cells/ml in serum-free medium as pellet cultures at
37uCi n5 %C O 2 in round-bottom tissue culture tubes.
Immunofluorescent intracellular staining and flow
cytometry
For combined surface and intracellular staining using the
unconjugated mAb to MxA, 1610
6 cells were fixed in 1%
paraformaldehyde, permeabilized with 0.2% Tween-20, and
stained intracellularly with a 1/500 dilution of mAb to MxA or
isotype control Ab for 20 min at 4uC as previously described [17].
The cells were washed with 0.2% Tween-20, and goat anti-mouse
FITC mAb was added at 10 ml/tube and incubated for 20 min at
4uC. Cells were washed with 0.2% Tween-20 and incubated for
10 min with 50 ml/tube of a 1/15 dilution of normal mouse IgG
(Caltag Laboratories). PE, PerCP, and APC-conjugated mAb were
added for 20 min at 4uC and washed with 0.2% Tween-20. Cells
were finally resuspended in FACS buffer before acquisition on a
FACSCalibur flow cytometer (BD Immunocytometry Systems).
For combined surface and intracellular staining using uncon-
jugated IRF-7, 1610
6 cells were first surface-immunophenotyped
with FITC, TC, or APC antibodies and fixed with 1%
paraformaldehyde. Cells were permeabilized with 0.2% Tween-
20 and incubated with 400 ng IRF-7 antibody for 40 minutes.
Cells were washed and incubated with 10 ml Goat anti-Rabbit PE
for 20 minutes. Cells were resuspended in FACS buffer before
acquisition on a FACSCalibur or LSRII flow cytometer.
For combined surface and intracellular staining using IFN-a-
biotin, 1610
6 cells were first surface-immunophenotyped with
FITC, PerCP-Cy5.5, PE-Cy7, APC, APC-Ax750, Pacific Blue and
eFluor650 nanocristal antibodies, then fixed with BD FACS
Lysing Solution. Cells were then permeabilized with BD FACS
Permeabilizing Solution 2 and incubated with 2 mg of IFN-a-
biotin (Thermo Scientific) or mouse IgG1 (BD Biosciences)
antibody for 20 minutes. Cells were then washed and incubated
with 5 ml of SAV-PE (BD Biosciences) for 10 minutes. Cells then
were washed and resuspended in FACS buffer before acquisition
on a LSRII (BD).
For combined surface and intracellular staining using PE
conjugated pSTAT1, 1610
6 cells were washed with FACS buffer
and surface-immunophenotyped with FITC and APC labeled
antibodies. The cells were fixed in 1.5% paraformaldehyde for 10
minutes at room temperature and permeabilized with 1 ml cold
(4uC) methanol for 10 minutes at 4uC. After washing the cells
twice with FACS buffer, they were stained with 10 ml pSTAT1-PE
or IgG2-PE control antibody for 30 minutes at room temperature.
The cells were resuspended in 250 ml FACS buffer before
acquisition on a FACSCalibur or LSRII flow cytometer.
Multiparameter data acquisition was performed with CellQuest
Constitutive IFN-a Expression in the Human Thymus
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FCS Express Version 3 (Denovo Software).
Immunofluorescence microscopy
Fetal tissues and post-natal thymus were fixed in formalin and
embedded in paraffin by the UCLA Tissue Procurement Core
Laboratory. Four mm sections were cut and placed on slides. The
slides were heated at 60uC for 30 minutes and washed in xylenes,
followed by rehydration in 100%, 95%, and 70% ethanol and
incubation in target retrieval solution pH 9.0 for 20 minutes at
95–99uC. Samples were stained with monoclonal antibodies to
MxA (1:500), IRF-7 (1:50), or LL-37 (1:50) and CD1a (1:50) or
CD27 (neat) overnight at 4uC. Samples were washed and stained
with secondary antibodies (1:250) for 4 hours at room tempera-
ture. Slides were mounted in fluorescence mounting medium and
coverslips were sealed with clear nail polish. For staining with
CD123 and MxA slides were stained first with CD123 (1:40)
overnight and washed. Slides were then stained with rabbit anti-
mouse IgG1 (1:500) for 2 hours followed by Goat anti Rabbit
AlexaFluor-594 for 2 hours. MxA was conjugated with Zenon anti
IgG2a AlexaFluor-488 following the manufacturer’s protocol.
Slides were stained for 2 hours and fixed with 2% paraformalde-
hyde for 10 minutes before samples were mounted in fluorescence
mounting medium and coverslips were sealed with nail polish.
Images were taken with a Zeiss compound microsope and
analyzed with Axiovision LE version 4.6 (Carl Zeiss Microima-
ging).
Immunohistochemistry
Postnatal thymus and fetal tissues were formalin fixed and
paraffin embedded. 4 um sections were mounted on slides and
stained with a monoclonal antibody to LL-37 (1:50) or CD19
(1:50) and control IgG2a antibody followed by biotinylated rabbit
anti-mouse antibody and streptavidin-biotin-peroxidase complex
using the DAKO Catalyzed Signal Amplification System.
Isolation and stimulation of thymic pDC
pDC were isolated from human thymus tissue by MACS-based
negative selection (Miltenyi). The purity of pDC was checked by
flow cytometry using CD45RA FITC, BDCA4-APC, CD123PE,
CD3 PerCP antibodies. Cells were stained with 7AAD to
determine the percentage of apoptotic cells.
pDC were stimulated with CpG-A(2216) oligonucleotides
(6 mg/ml) or LL-37 (10 mg) in the presence or absence of DNAse
I (Sigma; final conc.5 mg/ml). LL37 premixed with 2 mg
autologous DNA (DNAsy Kit, Qiagen) (peptide: DNA mass ratio
of 5:1) and incubated 30 min. at room temperature (50 mg/ml of
LL-37 and 10 mg/ml of DNA final concentration) was added to
pDC in some experiments. After overnight culture (18–20 hours)
at 37uC, 5%CO2 IFN-a level was measured by enzyme-linked
immunosorbent assay (ELISA; PBL Biomedical Laboratories).
Remaining cells were frozen in Trizol and used to isolate RNA for
quantitative real-time PCR for MxA expression.
To obtain a purified population of pDC the cells were first
enriched with BDCA4 selection kit (Miltenyi) followed by cell
sorting of CD123
+CD45RA
+ cells using a FACSAria II cell sorter
(Becton Dickinson). The purity of sorted pDC exceeded 95%.
pDC were stimulated with CpG-A(2216) oligonucleofo-
tides (10 mg/ml) or LL-37 peptide (Netherlands Cancer Insti-
tute) (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES)
(50 mg/ml) in the presence or absence of DNAse I (Roche)
(2000 U/ml) and RNAse (Roche) (50 ug/ml).
LL-37 (50 mg/ml) was premixed with eukaryotic DNA (10 mg/
ml) and RNA from cell line supernatant for 30 min. at room
temperature and added to pDC in some experiments. After
4 hours of culture at 37uC, 5% CO2 pDC were resuspended in
Trizol. RNA was isolated and cDNA synthesis was performed by
using the transcription high fidelity cDNA synthesis kit (Roche).
RNA isolation and real-time PCR
10610
7 cells were frozen in TriReagent (Invitrogen) and stored
at 280uC until RNA was isolated, when samples were incubated
with poly-acryl carrier for 5 minutes at room temperature, 100 ul
1-Bromo-3-chloropropane per mL of TriReagent was added for
10 minutes, spun at 12,000 g for 10 minutes at 4uC and the
aqueous phase was transferred to a fresh tube. 500 uL of
isopropanol was added for 10 minutes and samples were spun at
12,000 g for 8 minutes at room temperature. Pellets were washed
with 75% ethanol and allowed to air dry before resuspension in
100 ml water.
Taq-man gene expression assays were used to measure gene
expression (Applied Biosystems). Real-time PCR for analysis of
MxA (Mx1 HS_00182073_m1) IFNA1 (Hs00256882_s1), IFNA2
(Hs00265051_s1) was performed following manufacturer’s instruc-
tions. 96 well plates were run on an ABI 7300 and analyzed with
the 7300 system software.
Q-PCR on sorted pDC and thymocytes for relative expression
of IFN-a and MxA mRNA was performed by Sybr Green
PCR (iCycler Bio-Rad CFX96). Primers: IFN-a:5 9-GACTC-
CATCTTGGCTGTGA-39,5 9- TGATTTCTGCTCTGACAA-
CCT-39, MxA: 59-GGTGGCTGAGAACAACCTGT-39,5 9-GG-
TCCTGCTCCACACCTAGA-39, Beta-Actin and GAPDH were





Non-parametric Spearman rank correlation was used to
compare percent MxA expression versus age of thymus tissue;
two sided Wilcoxon-Mann-Whitney test to compare mean total
MxA expression between males and females; two sided Wilcoxon
signed rank sum test and sign test to compare mean fluorescence
intensity of MxA in thymocyte subsets.
Results
Expression of MxA in thymus, but not peripheral
lymphoid organs
Previously we observed that IFN-a was detected in normal
human fetal thymus/liver implants from SCID-hu mice [17]. The
current study was designed to obtain further insight in the
localization of endogenous constitutively produced IFN-a, the cell
type and the mechanism of induction in the thymus. The inability
to reliably detect all IFN-a subtypes and differences in the kinetics
of IFN-a secretion by different cell types makes the study of IFN-a
secretion technically challenging. However, studies have shown
that the ISG MxA is only synthesized in the presence of type I
IFNs, and is absent when type I IFNs are not secreted [9] and
requires signaling though STAT1 [33]. Hence, we first set out to
analyze the expression of MxA as a surrogate marker to detect the
presence of secreted type I interferons.
We confirmed that type I IFNs are constitutively secreted in the
thymus by analysis of intracellular MxA expression using flow
cytometry (Fig.1). We extended these findings by showing that
postnatal (18/18 donors, age 1 day-30 years) and fetal thymus (3/3
donors) expressed MxA (Fig.1A). While MxA was detected in all
thymus tissues (range 0.9–45%), there was no correlation between
Constitutive IFN-a Expression in the Human Thymus
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2=0.0301, p=0.46) (Fig. 1A) or
mean total MxA expression and sex (p=0.80) (Fig. 1B).
The presence of IFN-a secretion and resulting MxA expression
in normal tissues may not be unique to the thymus. To investigate
this, we compared the MxA expression in different lymphoid
tissues by staining postnatal thymus and fetal thymus, spleen, and
lymph node from the same fetal donor. In 3/3 experiments, only
the thymus, but not spleen or lymph node from the same fetal
donor expressed MxA (Fig. 1C). Also adult PBMC (n=3) (Fig. 1C)
lacked MxA expression. These findings were confirmed at the
RNA level by real time PCR (data not shown). Thus, MxA
expression in the thymus is not a result of localization of cells
within lymphoid tissue as both fetal spleen and lymph nodes lack
MxA expression. This finding is of note since fetal tissue by
definition is devoid of bacterial or viral infections, yet the presence
of MxA in the thymus suggests that IFN-a/b is secreted
constitutively.
MxA expression is located in the thymic medulla
To determine whether type I IFNs are secreted in specific
regions in the thymus in vivo, we performed immunofluorescence
microscopy using an anti-MxA monoclonal antibody. Fetal,
postnatal, and adult thymus tissues were stained with CD1a to
distinguish the cortex and CD27 to distinguish the medulla. In 3/3
fetal and 9/9 postnatal thymus samples (age 3 months-30 years)
MxA co-localized with the CD27
+ thymocytes in the medulla
(Fig.2A), but not with the CD1a
+ thymocytes in the cortex
(Fig. 2B). Within the medulla, both CD27
+ and CD27
2 cells
expressed MxA (Fig. 2A). To confirm these results, post-natal
thymus tissue sections were also stained for expression of IRF-7, a
factor required for the transcription of downstream interferon
stimulated genes including MxA [2]. Like MxA, IRF-7 was
preferentially expressed in the medulla, but not in the cortex (data
not shown). Localization of MxA and IRF-7 in areas of the thymus
that stain with CD27 confirms that IFN-a/b is secreted within the
thymic medulla.
MxA, IRF-7, and phosphorylated STAT1 are preferentially
expressed in mature thymocytes
We and others have shown that most thymocyte subsets express
the receptor for IFN-a (CD118) and can respond to stimulation
with type I IFNs [17]
,[34]. If IFN-a is secreted throughout the
thymic cortex and medulla then the phenotype of MxA expressing
cells should match the phenotypic distribution of all developing
thymocytes. To determine the immunophenotypic profile of MxA
expressing cells, total thymocytes were stained for cell surface
expression of CD4, CD8, CD1a, CD3, CD27, CD45RA and
CD123 in combination with intracellular MxA expression. We
observed that MxA is preferentially expressed in cells that exhibit a






+) (Fig. 3A). Furthermore, when focusing on the
mature, medullary, thymocyte subsets (ie. CD27
+ cells), MxA





+ cells that are ready to emigrate from the thymus
to the periphery (Fig. 3B). These data are consistent with the
notion that type I IFNs are secreted locally in the medulla.
We also assessed expression of phosphorylated STAT1
(pSTAT1) and IRF-7, which are upstream of MxA, and
dependent on signals received from the type I IFN receptor [2].
Phosphorylated STAT1 (Fig. S1A) and IRF-7 were also
Figure 1. Constitutive expression of MxA in thymocytes. A,B, Total thymocytes were isolated from fetal and postnatal thymus tissues. Cells
were stained for surface expression of CD3, CD4, CD8 and intracellular expression of MxA ex vivo. Three fetal and 18 postnatal thymus tissues were
examined to determine the effect of age (A) and sex (B) on MxA expression. C, Cells from postnatal thymus, fetal thymus spleen and lymph node
tissues and adult PBMC were stained for intracellular expression of MxA. Fetal tissues were obtained from the same donor.
doi:10.1371/journal.pone.0024252.g001
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mounted on slides. A, Thymus tissue was stained with CD1a and MxA followed by Goat anti-mouse IgG1 Alexa Fluor 488 and Goat anti-mouse IgG2a
Alexa Fluor 594. B, Thymus tissue was stained with antibodies directed against CD27 and MxA followed by Goat ant-mouse IgG1 Alexa Fluor 488 and
Goat anti-mouse IgG2a Alexa Fluor 594.
doi:10.1371/journal.pone.0024252.g002
Figure 3. MxA is preferentially expressed in mature thymocytes and exogenous IFN-a only upregulates MxA in immature
CD1a
+CD27
2 thymocytes. A, B, Total thymocytes were stained for surface expression of CD4, CD8, CD1a, CD3, CD27, CD45RA and CD123
combined with intracellular MxA expression. A, Differences of thymocyte subset expression patterns in all thymocytes, MxA negative and positive
cells are shown. B, Differences of thymocyte subset expression patterns in CD27
+, MxA negative and positive cells are shown. C, Total thymocytes
were cultured in the presence or absence of 1000 U/mL IFN-a overnight. Cells were stained for surface expression of CD4, CD8, CD1a, CD3, CD27,
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ing the expression pattern observed with MxA. Taken together,
the presence of MxA, pSTAT1 and IRF-7 support the notion that
type I IFNs are constitutively secreted in the thymus. Furthermore,
the phenotype of the cells that have responded to type I IFNs and
as a result phosphorylate STAT1 and express MxA and IRF-7 ex
vivo suggest that type I IFNs are secreted locally within the medulla
where mature thymocytes are located.
Stimulation of thymocytes with exogenous IFN-a
upregulates MxA and pSTAT1
While all thymocyte subsets express CD118, we cannot exclude
the possibility that immature thymocytes may not respond to
stimulation by IFN-a. To test this notion, thymocytes were
stimulated with 1000 U/mL recombinant IFN-a overnight and
stained for surface expression of CD4, CD8, CD1a, CD3, CD27,
CD45RA and CD123 combined with intracellular MxA expres-
sion. Stimulation with exogenous IFN-a showed a robust increase
in total MxA expression in CD27
2CD1a
+ thymocytes, confirming
the ability of immature thymocytes to respond to IFN-a. Notably,
no further increase in MxA expression in CD27
+CD1a
2 mature
thymocytes was observed (Fig. 3C). Similarly, pSTAT1 levels
increased in immature, but not in mature thymocytes after
stimulation with 1000 U/mL exogenous IFN-a (data not shown).
These results indicate that all thymocytes have the potential to
respond to IFN-a ex vivo. However in vivo, immature thymocytes
are less stimulated and mature thymocytes may have already been
stimulated to maximal levels by constitutively produced IFN-a.
pDC express IFN-a and higher levels of MxA in the
thymus compared to other thymocyte subsets
We have previously shown that thymic pDC are necessary for
the expression of MxA in response to HIV-1 infection of the
thymus [17]. Their role as the natural interferon producing cells
suggests that thymic pDC are likely involved in the constitutive
secretion of IFN-a and subsequent expression of MxA by
thymocytes. Using real-time PCR analysis, we observed that
IFN-a mRNA is transcribed in the thymus and that IFN-a
transcripts are preferentially transcribed in MACS enriched or
sorted pDC compared to total thymocytes or non-pDC (Fig. S2).
To confirm IFN-a protein expression in pDC, we electronically
gated on CD123
+CD45RA
+ thymocytes which lacked expression
of CD1a and CD3, the phenotype of pDC. As can be seen in
Figure 4A, .88% of pDC expressed IFN-a, while non-pDC did
not. Since it is known that pDC themselves are able to respond to
type I IFNs, it is expected that pDC express MxA. By flow
cytometry we measured MxA and pSTAT1 expression ex vivo in
pDC (identified here as CD45RA
+CD123
+/hi cells), isolated from
post-natal thymus tissues and found that (8969%) of pDC are
MxA positive (n=15) (Fig. 4B). In addition,MxA mRNA was also
measured and observed to be expressed at high levels in pDC (Fig.
S2). Post-natal thymic pDC also expressed pSTAT1 (Fig. 4B) and
IRF-7 (data not shown). Furthermore, thymic pDC showed a
significantly higher MxA mean fluorescence intensity (3–13 fold,
p,0.00001, (n=15)) than other MxA positive thymocyte subsets
(Fig. 4C).
To confirm our observation that pDC express high levels of
MxA in the thymus, but not in other lymphoid tissues, we stained
single cell suspensions from fetal tissues or adult PBMC for surface
expression of CD123, CD45RA, CD3 and intracellular expression
of MxA. MxA expression in pDC was determined by gating on
CD45RA
+CD123
+/hi cells that lacked CD3. We observed that in
3/3 experiments pDC from the thymus were MxA positive, while
pDC from autologous fetal spleen and lymph node lacked MxA
expression (Fig. S3). Adult peripheral blood pDC also lacked MxA
expression (Fig. S3) and a lack of MxA expression was also
observed in Cord blood (data not shown).
To verify MxA expression in thymic pDC and to analyze co-
localization with MxA positive thymocytes, post-natal thymus
tissue was stained with CD123 and anti-MxA antibodies. In line
with previous findings, pDC (CD123
+) are located within the
medulla and at the cortico-medullary junction, but not found
within the cortex (Fig. 4D) [18,19,35]. As expected from the flow
cytometric data, the majority of cells that express high levels of
CD123 also expressed MxA (Fig. 4D, Arrows). Moreover, pDC
were located in close proximity to thymocytes that expressed MxA
(Fig. 4D, Merge). The co-localization of pDC with MxA positive
cells in the medulla suggests that pDC are directly responsible for
the secretion of IFN-a in the thymus. Furthermore, the finding
that MxA is highly expressed in thymic pDC adds value to the
notion that type I IFN can act in an autocrine or paracrine
manner as a pDC survival factor and is in agreement with a
previous report [36].
The anti-microbial peptide LL-37 co-localizes with pDC in
the medulla
Our data suggest that there is a thymus-specific trigger for pDC
to induce IFN-a/b secretion. Recent publications demonstrated
that the anti-microbial peptide LL-37 isolated from psoriasis skin
lesions can bind eukaryotic DNA and RNA and trigger peripheral
blood pDC to secrete IFN-a in a TLR-9 dependent manner
[29,30]. We hypothesized that expression of LL-37 in the thymus
could result in interferon secretion, since DNA/RNA would be
readily available from medullary thymocytes undergoing apoptosis
as a result of negative selection. To assess whether and where LL-
37 protein is expressed, thymic tissue sections were stained with an
anti- LL-37 monoclonal antibody. We found that LL-37 was
mainly expressed in the medulla in the fetal thymus, although
some expression was also observed in the cortex by immunoflu-
orescence (data not shown) and immunohistochemistry (Fig. 5,
brown staining). Thus the combined presence of pDC, LL-37, and
autologous DNA/RNA derived from negatively selected thymo-
cytes in the medulla can explain the presence of MxA in normal
thymus tissue. While LL-37 was not detected in the fetal lymph
node (same donor as fetal thymus), it was found in several (n=3)
non-B (CD19
+) cell zones of the fetal spleen. We speculate that
there is likely no/little apoptosis occurring in the fetal spleen
resulting in no/limited amounts of autologous DNA/RNA. This
could account for the observed lack of MxA expression in
lymphocytes and pDC in the fetal spleen (Fig. 1 and Fig. S3).
Exogenous LL-37 complexed with DNA/RNA upregulates
IFN-a
Based on findings that IFN-a production by peripheral pDC
can be induced by LL-37 complexed with eukaryotic DNA or
RNA [29,30], we examined whether exogenous LL-37 complexed
with eukaryotic DNA/RNA increases IFN-a secretion by thymic
pDC. PDC were sorted from thymus and stimulated with LL-37
complexed with DNA/RNA obtained from supernatants of
apoptotic cells. After 6 hours of culture, we detected 9.1-fold
more IFN-a transcripts compared to either medium or eukaryotic
DNA/RNA alone (Fig. 6). Notably, pretreatment of the
supernatant containing eukaryotic DNA/RNA with DNAse and
RNAse partially inhibited IFN-a mRNA expression. Stimulation
with the TLR9 agonist CpG-A (2216), which was used as a
positive control, induced 3-fold higher levels of IFN-a expression
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tion, we found that autologous DNA from apoptotic thymocytes
complexed with LL-37 induced MxA mRNA expression and IFN-
a production in the supernatant of cultured pDC (data not shown).
Collectively, these results provide evidence for the notion that LL-
37 when complexed with DNA/RNA is able to increase IFN-a
production, which may subsequently induce MxA expression in
the medulla of the thymus. Notably, while stimulation of pDC with
CpG-A also resulted in the production of TNF-a, stimulation with
LL-37 complexed with DNA/RNA did not (Fig. 6). This result
suggests that thymic pDC do not promote a pro-inflammatory
state in the thymic medulla.
Discussion
Here we show that the interferon induced protein MxA is
constitutively expressed in post-natal and fetal thymus, but not in
peripheral lymphoid tissues including fetal spleen and lymph nodes
(from the same donor as the thymus). In addition, we show that the
majority of thymic pDC express high levels of IFN-a. This
together with their medullar localization strongly suggests that
thymic pDC are responsible for inducing MxA expression
exclusively in the medulla. Finally, we observed that the anti-
microbial peptide LL-37 is expressed in the thymus, and that this
in complex with eukaryotic DNA/RNA can stimulate thymic pDC
to express IFN-a in vitro. Collectively, our findings imply that type I
IFNs, which are constitutively expressed in the medulla, may have
a direct role on the development of T cells in the thymus.
MxA has been used as a reliable marker to detect type I IFN in
clinical settings, including SLE and hepatitis C infection [37,38],
as it is exclusively expressed after engagement of type I IFNs to its
receptor [9]. Hence, we conclude that type I IFNs are
constitutively expressed in the thymus, but not in the spleen or
lymph node. This is consistent with our previous observations that
IFN-a expressing pDC are present in the human fetal thymus/
liver implant in the SCID-hu mouse [17]. Our conclusion is
further enforced by the findings that pSTAT1 and IRF-7, which
are both activated upon type I IFN signaling, are expressed in the
normal thymus [33]. The fact that not only post-natal but also fetal
thymus tissue harbors a type I IFN stimulated gene signature
endorses the notion that this phenomenon occurs in the absence of
viral or bacterial infection and is further supported by the presence
of ‘‘immunoreactive’’ IFN-a in fetal thymus tissues described
many years ago [39].
A notable finding in our study is that MxA expressing
thymocytes (Fig.1) and pDC (Fig. S3), were only present in fetal
and postnatal thymus tissues, but not in fetal spleen or lymph node
or in adult peripheral blood. This prompted us to search for a
stimulus which was only present in the thymus, but not in the
peripheral lymphoid organs. We considered the antimicrobial
peptide LL-37 as a potential candidate based on a recent report
that LL-37 isolated from psoriasis skin lesions can bind DNA and
Figure 4. Thymic pDC constitutively express IFN-a, MxA and pSTAT1. A, pDC from post-natal thymus express IFN-a. Total thymocytes were
stained for surface expression of CD123, CD45RA, CD4, CD8, CD27, CD1a and CD3 and intracellular expression of IFN-a. IFN-a expression of pDC was
determined by gating on CD45RA
+CD123
+/hi cells, that lacked CD3 and CD1a. B, pDC from post-natal thymus express MxA and pSTAT1. Total
thymocytes were stained for surface expression of CD45RA, CD123, and CD3 and intracellular expression of MxA or pSTAT1. MxA and pSTAT1
expression in pDC was determined by gating on CD45RA
+CD123
+/hi cells that lacked CD3. C, pDC express the highest level of MxA. Total thymocytes
were stained for surface expression of CD45RA, CD123, and CD3 and intracellular expression of MxA. Mean fluorescence intensity (MFI) of MxA
expression in pDC was determined by gating on CD3
2CD45RA
+CD123
+/hi cells. MxA MFI expression in mature and immature thymocyte subsets was





low/2 cells. D, pDC are located in the medulla of normal thymus. Thymus tissue
was formalin fixed and paraffin embedded. 4 um sections were mounted on slides. Thymus tissue was stained for CD123 followed by Rabbit anti-
mouse IgG1 and Goat anti-Rabbit Alexa Fluor 594. MxA was conjugated with zenon anti-IgG2a Alexa 488.
doi:10.1371/journal.pone.0024252.g004
Figure 5. LL-37 is located in the cortex and medulla of the thymus and in non-B cell zones of the fetal spleen. Fetal thymus, spleen, and
lymph nodes were formalin fixed and paraffin embedded. 4 um sections were mounted on slides and stained with a monoclonal antibody to LL-37 or
CD19 followed by biotinylated rabbit anti-mouse antibody and streptavidin-biotin-peroxidase complex. IgG2a was used as control antibody. (C)
cortex; (M) medulla. The fetal tissues were obtained from the same donor.
doi:10.1371/journal.pone.0024252.g005
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The same group reported that eukaryotic RNA/LL-37 complexes
trigger the secretion of IFN-a by pDC through TLR7 activation
[30]. More recently it was demonstrated that IFN-a secretion in
response to CpG-ODNs can also be mediated by the cytosolic
sensors aspartate-glutamate-any amino acid-aspartate/histidine
(DExD/H)-box helicase 36 (DHX36) and DHX9, which is
TLR7 and 9 independent but MyD88 dependent [40]. CAMP1,
the gene encoding LL-37, is expressed in many tissues with the
highest expression levels in bone marrow and thymus [31]. Our
results show that LL-37 is mainly expressed in the thymic medulla,
although some expression was also observed in the cortex. The co-
localization of pDC and LL-37 in the thymic medulla where
nucleic acids may be present from thymocytes undergoing
apoptosis as a result of negative selection [32], suggests that LL-
37 is a likely trigger for the constitutive secretion of IFN-a in the
thymus. Although it is known that macrophages will rapidly
phagocytose apoptotic cells, we previously showed that apoptotic
CD4
+ thymocytes can be identified in the human thymus [41]. We
also found LL-37 expression in the fetal spleen, but as there is little
apoptosis in this organ, it can be assumed that the lack of DNA
accounts for the lack of IFN-a secretion and subsequent MxA
expression in the fetal spleen.
We previously reported that MxA is highly expressed in pDC
and mature thymocytes in response to CpG or HIV-1 induced
type I IFN production [17]. In the current study we show that
pDC constitutively express IFN-a in the absence of microbial
stimulation, and are likely the main source of IFN-a secretion in
the thymus. The observation that pDC in normal thymus express
high levels of MxA indicates that they also responded to secreted
IFN-a in an autocrine fashion. This is consistent with the notion
that pDC employ type I IFNs for their survival [36]. It is of note,
that the mean fluorescence intensity of MxA is significantly higher
in pDC than in other thymocyte subsets, although the explanation
for this is currently unclear. It is possible that this can be attributed
to increased responsiveness to type I IFNs due to higher expression
levels of the type I IFN receptor or downstream signaling
molecules. Alternatively, it can be envisioned that negative
regulators of the JAK/STAT pathway, such as SOCS proteins,
are differentially activated in pDC compared to thymocytes.
Our current data using immunofluorescence, and those of
Meager et al [42], indicate that MxA expressing cells are mainly
present in the thymic medulla. We confirmed these findings by
flow cytometry as detailed characterization of MxA
+ cells enriches






+. Meager et al. [42], in a study of anti-interferon
autoantibodies in autoimmunity, showed that resident macro-
phages expressed IFN-a in the postnatal thymus, but did not
express MxA and are therefore likely only storing IFN-a and not
actively secreting it. The data presented here suggest that IFN-a is
continuously produced in the thymic medulla by pDC resulting in
MxA expression in medullary thymocytes and pDC. However it is
still unclear what role this cytokine plays in thymopoiesis in vivo.
We previously reported that IFN-a is a reversible inhibitor of
human T cell development [16]. Murine studies found that
exogenous IFN-a interfered with early T and B cell development
at stages where IL-7 stimulation is necessary [13]. Utilizing the
OP-9 culture system to mimic thymopoiesis in vitro, we showed that
IFN-a inhibits early stages of thymocyte development as it delayed
the acquisition of CD1a on developing CD34
+ thymic progenitor
cells [16]. In addition we found that IFN-a inhibited later stages of





Cells of these developmental stages, which are present at the
cortico-medullary junction, coincide with stages where thymocytes
are responsive to IL-7 induced proliferation. Taken together, these
data suggest that IFN-a may serve to control the rate of
thymopoiesis. Another attractive consideration is that IFN-a
secretion may play a role in negative selection. Autoreactive T
cells are negatively selected in the medulla and are removed via
apoptosis (reviewed in[43]) induced by several mechanisms
including TRAIL-mediated cell death (reviewed in[44]). This is
consistent with reports demonstrating that the expression of MxA
increases a cell’s susceptibility to cell death [45,46]. Hence, it is
possible that mature MxA
+ thymocytes may be more sensitive to
cell death as a result of MxA expression. The increased
susceptibility to cell death may reduce the signal intensity
necessary to delete autoreactive T cells. The expression of MxA
in mature thymocytes may aid in reducing the threshold needed
for negative selection.
Finally, we believe that our data have implications in the
pathogenesis of CCR5-tropic compared to CXCR4-tropic HIV-1
infection in the thymus. Previously we reported that the
proportion of pDC expressing IFN-a increased after infection
with either CXCR4 or CCR5-tropic HIV-1 [17]. We and others
have shown that infection with CCR5-tropic viruses leads to
infection of mature thymocytes within the thymic medulla
[47,48,49,50]. We speculate that the constitutive expression of
ISG in the medulla may make this region relatively more resistant
to infection. This notion is in line with the reduced pathogenicity
of CCR5-tropic strains when compared to CXCR4-tropic strains
[50,51]. In contrast, CXCR4-tropic strains may be more
pathogenic due to the fact that they initially infect cells located
within the cortex where we did not observe constitutive ISG
expression [47,49,51,52]. It is tempting to speculate that by
infecting cells that are distantly located from pDC and the ISG,
these virus strains are able to replicate much more efficiently. This
suggests that constitutive IFN-a secretion, in addition to its
potential role in T cell development, is essential in inhibiting acute
infection with CCR5-tropic HIV-1.
Supporting Information
Figure S1 pSTAT1 and IRF-7 are preferentially ex-
pressed in mature thymocytes. Total thymocytes were
Figure 6. LL-37 upregulates the expression of IFN-a, but not
TNF-a in thymic pDC. Sorted pDC were incubated with LL-37 plus or
minus eukaryotic DNA/RNA or LL-37-DNA/RNA complex pretreated with
DNAse and RNAse. CpG-A 2216 was used as a positive control. Q-PCR
was performed for IFN-a and TNF-a mRNA.
doi:10.1371/journal.pone.0024252.g006
Constitutive IFN-a Expression in the Human Thymus
PLoS ONE | www.plosone.org 9 August 2011 | Volume 6 | Issue 8 | e24252stained for surface expression of CD4, CD8, CD1a, CD3 and
CD27 and intracellular expression of pSTAT1 (A) or IRF-7 (B).
Differences of thymocyte subset expression patterns in all
thymocytes and pSTAT1 and IRF-7 negative and positive cells
are shown.
(TIF)
Figure S2 Thymic pDC constitutively express high
levels of IFN-a mRNA. mRNA was prepared from postnatal
total thymocytes, BCDA4-MACS enriched pDC and the BDCA4
negative fraction, and from sorted pDC. Q-PCR was performed
for IFN-a mRNA.
(TIF)
Figure S3 pDC from post-natal and fetal thymus
express MxA, but not pDC from fetal spleen or fetal
lymph node or adult PBMC. Cells from fetal tissues or adult
PBMC were stained for surface expression of CD123, CD3 and
CD45RA and intracellular expression of MxA. MxA expression in
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